Pharmacological modulation of ferroptosis as a therapeutic target for liver fibrosis

被引:13
|
作者
Li, Le [1 ,2 ]
Zhu, Zhijun [1 ]
机构
[1] Capital Med Univ, Liver Transplantat Ctr, Clin Res Ctr Pediat Liver Transplantat, Natl Clin Res Ctr Digest Dis,Beijing Friendship Ho, Beijing, Peoples R China
[2] Chifeng Municipal Hosp, Dept hepatobiliary Surg, Chifeng, Peoples R China
关键词
liver fibrosis; liver transplantation; ferroptosis; ferroptosis inducer; treatment; bioactive compounds; STELLATE CELL ACTIVATION; TGF-BETA; INFLAMMATION; PROTEIN; DEGRADATION; PATHWAY; INJURY;
D O I
10.3389/fphar.2022.1071844
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Liver fibrosis, which is characterized by the excessive deposition of extracellular matrix (ECM) materials (primarily fibrillar collagen-I), is an abnormal repair reaction and pathological outcome of chronic liver diseases caused by alcohol abuse, non-alcoholic fatty liver disease, and chronic hepatitis B and C virus infections. Liver fibrosis often progresses to liver cirrhosis and hepatocellular carcinoma. Ferroptosis, characterized by lipid peroxidation, is a form of iron-dependent non-apoptotic cell death, and recent studies have reported that ferroptosis contribute to the development of liver fibrosis. Moreover, several agents have demonstrated therapeutic effects in experimental liver fibrosis models by inducing hepatic stellate cell (HSCs) ferroptosis. This review delineates the specific mechanism by which ferroptosis contributes to the development of liver fibrosis. Specifically, we focused on the different types of therapeutic agents that can induce HSCs ferroptosis and summarize their pharmacological effectiveness for liver fibrosis treatment. We suggest that HSCs ferroptosis may be a potential useful target of novel therapies for preventing and treating liver fibrosis.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Epigenetics in Liver Fibrosis: Could HDACs be a Therapeutic Target?
    Claveria-Cabello, Alex
    Colyn, Leticia
    Arechederra, Maria
    Urman, Jesus M.
    Berasain, Carmen
    Avila, Matias A.
    Fernandez-Barrena, Maite G.
    CELLS, 2020, 9 (10) : 1 - 20
  • [22] Ferroptosis in organ fibrosis: From mechanisms to therapeutic medicines
    Lai, Weijing
    Wang, Bo
    Huang, Rongshuang
    Zhang, Chuyue
    Fu, Ping
    Ma, Liang
    JOURNAL OF TRANSLATIONAL INTERNAL MEDICINE, 2024, 12 (01) : 22 - 34
  • [23] 14-kDa phosphohistidine phosphatase is a potential therapeutic target for liver fibrosis
    Xu, Anjian
    Zhou, Jichao
    Li, Yanmeng
    Qiao, Luyao
    Jin, Caicai
    Chen, Wei
    Sun, Lan
    Wu, Shanna
    Li, Xiaojin
    Zhou, Donghu
    Jia, Siyu
    Zhang, Bei
    Yao, Jingyi
    Zhang, Xiaowei
    You, Hong
    Huang, Jian
    AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2021, 320 (03): : G351 - G365
  • [24] Liver fibrosis - Pathogenesis and novel therapeutic approaches
    Tacke, F.
    Weiskirchen, R.
    INTERNIST, 2010, 51 (01): : 21 - 29
  • [25] Therapeutic Implications of Ferroptosis in Renal Fibrosis
    Zhang, Yao
    Mou, Yanhua
    Zhang, Jianjian
    Suo, Chuanjian
    Zhou, Hai
    Gu, Min
    Wang, Zengjun
    Tan, Ruoyun
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2022, 9
  • [26] miR-29, a potential therapeutic target for liver fibrosis
    Bian, Er-Bao
    Li, Jia
    Zhao, Bing
    GENE, 2014, 544 (02) : 259 - 260
  • [27] BRD4 is a novel therapeutic target for liver fibrosis
    Ding, Ning
    Hah, Nasun
    Yu, Ruth T.
    Sherman, Mara H.
    Benner, Chris
    Leblanc, Mathias
    He, Mingxiao
    Liddle, Christopher
    Downes, Michael
    Evans, Ronald M.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2015, 112 (51) : 15713 - 15718
  • [28] Therapeutic targets in liver fibrosis
    Fallowfield, Jonathan A.
    AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2011, 300 (05): : G709 - G715
  • [29] Ferroptosis as a Therapeutic Target in Subarachnoid Hemorrhage
    Ohadi, Mohammad Amin Dabbagh
    Maroufi, Seyed Farzad
    Mohammadi, Mohammad Reza
    Siyanaki, Mohammad Reza Hosseini
    Khorasanizadeh, MirHojjat
    Kellner, Christopher P.
    WORLD NEUROSURGERY, 2024, 182 : 52 - 57
  • [30] HMGB2 is a potential diagnostic marker and therapeutic target for liver fibrosis and cirrhosis
    Huang, Yi
    Liangpunsakul, Suthat
    Rudraiah, Swetha
    Ma, Jing
    Keshipeddy, Santosh K.
    Wright, Dennis
    Costa, Antonio
    Burgess, Diane
    Zhang, Yuxia
    Huda, Nazmul
    Wang, Li
    Yang, Zhihong
    HEPATOLOGY COMMUNICATIONS, 2023, 7 (11) : e0299